DE60130976D1 - Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs - Google Patents

Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs

Info

Publication number
DE60130976D1
DE60130976D1 DE60130976T DE60130976T DE60130976D1 DE 60130976 D1 DE60130976 D1 DE 60130976D1 DE 60130976 T DE60130976 T DE 60130976T DE 60130976 T DE60130976 T DE 60130976T DE 60130976 D1 DE60130976 D1 DE 60130976D1
Authority
DE
Germany
Prior art keywords
treatment
cancer
protein transferase
transferase inhibitors
farnesyl protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60130976T
Other languages
English (en)
Other versions
DE60130976T2 (de
Inventor
David William End
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE60130976D1 publication Critical patent/DE60130976D1/de
Publication of DE60130976T2 publication Critical patent/DE60130976T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60130976T 2000-02-24 2001-02-20 Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs Expired - Lifetime DE60130976T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18455100P 2000-02-24 2000-02-24
US184551P 2000-02-24
PCT/EP2001/001937 WO2001062234A2 (en) 2000-02-24 2001-02-20 Dosing regimen

Publications (2)

Publication Number Publication Date
DE60130976D1 true DE60130976D1 (de) 2007-11-29
DE60130976T2 DE60130976T2 (de) 2008-07-17

Family

ID=22677368

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130976T Expired - Lifetime DE60130976T2 (de) 2000-02-24 2001-02-20 Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs

Country Status (9)

Country Link
US (1) US6838467B2 (de)
EP (1) EP1267848B1 (de)
JP (1) JP2003523381A (de)
AT (1) ATE375794T1 (de)
AU (1) AU2001231763A1 (de)
CA (1) CA2397558A1 (de)
DE (1) DE60130976T2 (de)
ES (1) ES2293972T3 (de)
WO (1) WO2001062234A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
US20030185831A1 (en) * 2001-11-30 2003-10-02 Schering Corporation Methods of treating cancer using an FPT inhibitor and antineoplastic
KR20070001922A (ko) 2003-12-12 2007-01-04 와이어쓰 심장혈관질환 치료에 유용한 퀴놀린
UA85570C2 (uk) * 2004-01-23 2009-02-10 Янссен Фармацевтика Н.В. Заміщені хіноліни та їх застосування як мікобактеріальних інгібіторів
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
EP1732549A4 (de) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
EP2076263A2 (de) * 2006-10-25 2009-07-08 Schering Corporation Diskontinuierliche verfahren zur behandlung von krebs
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
PL2909192T3 (pl) 2012-10-16 2017-09-29 Janssen Pharmaceutica Nv Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
WO2015057629A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3285768B1 (de) 2015-04-21 2020-12-30 Eiger Biopharmaceuticals, Inc. Pharmazeutische zusammensetzungen mit lonafarnib und ritonavir
DK3277842T5 (da) 2015-08-17 2020-08-31 Kura Oncology Inc Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
KR20190082247A (ko) 2016-11-03 2019-07-09 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR102003179B1 (ko) 2017-02-21 2019-07-23 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
JP7325400B2 (ja) 2017-08-07 2023-08-14 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CN113286591A (zh) 2018-11-01 2021-08-20 库拉肿瘤学公司 用法尼基转移酶抑制剂治疗癌症的方法
JP2022514654A (ja) 2018-12-21 2022-02-14 クラ オンコロジー， インコーポレイテッド 扁平上皮癌のための治療法
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
KR20210144778A (ko) 2019-03-29 2021-11-30 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5834434A (en) * 1993-05-18 1998-11-10 University Of Pittsburgh Inhibitors of farnesyltransferase
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
ES2175137T3 (es) 1995-12-08 2002-11-16 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa.
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
ATE252104T1 (de) 1996-12-20 2003-11-15 Tovarischestvo S Ogranichennoi Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12- lid- hydrochlorid
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
DE69838025T2 (de) 1997-04-25 2008-05-08 Janssen Pharmaceutica N.V. Chinazolinone die farnesyltransferase hemmen
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
WO2000001691A1 (en) 1998-07-01 2000-01-13 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
CA2341739C (en) 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
OA11645A (en) 1998-08-27 2004-11-16 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
EE04962B1 (et) 1998-12-23 2008-02-15 Janssen Pharmaceutica N.V. Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks

Also Published As

Publication number Publication date
CA2397558A1 (en) 2001-08-30
US6838467B2 (en) 2005-01-04
JP2003523381A (ja) 2003-08-05
DE60130976T2 (de) 2008-07-17
US20030060450A1 (en) 2003-03-27
WO2001062234A2 (en) 2001-08-30
EP1267848A1 (de) 2003-01-02
WO2001062234A8 (en) 2001-09-27
AU2001231763A1 (en) 2001-09-03
EP1267848B1 (de) 2007-10-17
ES2293972T3 (es) 2008-04-01
ATE375794T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
DE60130976D1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60219595D1 (de) Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
DE69912790D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von arthropathien
MY169308A (en) Treatment of tnf? related disorders
DK0677039T3 (da) Cyclobutanderivater som squalen-syntetase- og protein-farnesyltransferaseinhibitorer
DE69533550D1 (de) Verfahren zur hemmung der krebsmetastasierung durch orale verabreichung von löslichem modifiziertem zitruspektin
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE60233650D1 (de) Verfahren zur behandlung von stoffwechselerkrankungen mit malonyl-coa-decarboxylase-hemmern
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
ATE382346T1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE443044T1 (de) Tace inhibitoren
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE60328772D1 (de) Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
ATE539756T1 (de) Prostaglandinsubstanzen für die behandlung von fettsucht
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
NO20024755D0 (no) Metode
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks

Legal Events

Date Code Title Description
8364 No opposition during term of opposition